ANMOL PATEL: Open Payments
NPI 1124873690 · LISLE, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$840 in 31 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $175 · 2025 $840
Food & beverage: $583Education: $258
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $192 |
| Janssen Biotech, Inc. | 4 | $146 |
| Celgene Corporation | 5 | $112 |
| Genentech USA, Inc. | 3 | $83 |
| Novartis Pharmaceuticals Corporation | 2 | $44 |
| ABBVIE INC. | 2 | $38 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| Dexcom, Inc. | 2 | $35 |
| JAZZ PHARMACEUTICALS INC. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
Products named: REBLOZYL, RYBREVANT, Tecentriq, Nubeqa, Dexcom G6 Transmitter, ZEPZELCA, ALUNBRIG, PLUVICTO.
Industry payments across IL — which companies pay providers there.
